San Francisco–Third Harmonic Bio, Inc. (Nasdaq: THRD) announced that its Board of Directors has approved a Plan of Liquidation and Dissolution, with a proposal to be submitted for stockholder approval at the company’s Annual Meeting on June 5, 2025.
Pending approval, the biotech company plans to liquidate its assets and distribute between approximately $246.6 million and $255.4 million—equivalent to $5.13 to $5.33 per share—to stockholders in an initial payout expected in the third quarter of 2025. Total potential distributions could reach up to $259.8 million, or $5.42 per share, subject to asset sale outcomes.
As part of the dissolution, Third Harmonic Bio intends to sell its remaining assets, including its THB335 program, following completion of Phase 2 readiness activities. CEO Natalie Holles stated that the decision reflects the board’s commitment to maximizing value for shareholders through an orderly wind-down and asset monetization process.
The company will file a Certificate of Dissolution in Delaware if the plan is approved and will delist from Nasdaq shortly thereafter. The board retains the right to abandon the plan at any time prior to its execution.
